David A. Siegel Intra Cellular Therapies, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 143,267 shares of ITCI stock, worth $18.9 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
143,267Holding current value
$18.9 Million% of portfolio
0.03%Shares
10 transactions
Others Institutions Holding ITCI
# of Institutions
418Shares Held
87.7MCall Options Held
284KPut Options Held
105K-
Vanguard Group Inc Valley Forge, PA9.72MShares$1.28 Billion0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$833 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.13MShares$676 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.25MShares$428 Million1.36% of portfolio
-
Norges Bank Oslo, Q83.21MShares$424 Million0.04% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $12.4B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...